Cell-free DNA as a cancer biomarker
Please note that for mobiles we stream the presentation slides and audio of the speaker.
You must login to watch this lecture.
Dr Urnovitz delivers a talk on the impact of next-generation sequencing for cancer, focusing on the work of his company, Chronix Biomedical. The techonology that is being developed allows for cancer biomarker discovery at an early phase and in real-time, providing more effective outcomes, and savings on healthcare costs.
Dr Urnovitz emphasises the importance of large data collection to allow technology to discover actionable mutations for future therapy targeting.
This lecture was part of the event 'Immuno-oncology: using the body's own weapons'. It was held at The Royal Society of Medicine in London.
Date of lecture: 15th April 2015
This video is available for iPad via Safari
Tips about RSM Videos
- This video is free to view for RSM Members, please log in before watching. There is a fee of £6.00 for Non-Members.
- This video is linked to a CPD credit. Both RSM members and non-members must login before watching the video to be able to claim a CPD credit.
- Click on the Slides tab to view all slides. You can make any slide larger by clicking on it.
- Click on the Chapters tab to view different parts of the video.